Primary Rosai-Dorfman Disease of Bone: A Report of Two Cases

Andrew B. Ross,1 Kirkland W. Davis,2 Darya Buehler,3 and Brian Y. Chan4

1Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave. MC 3252, Clinical Science Center, Madison, WI 53792, USA
2Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
3Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
4Department of Radiology, University of Utah, Salt Lake City, UT, USA

Correspondence should be addressed to Andrew B. Ross; aross@uwhealth.org

Received 16 July 2018; Revised 30 November 2018; Accepted 11 December 2018; Published 3 January 2019

Academic Editor: Roberto Iezzi

Copyright © 2019 Andrew B. Ross et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Rosai-Dorfman disease (RDD), sometimes known as sinus histiocytosis with massive lymphadenopathy, is a rare histiocytic disorder that most commonly presents as painless, massive cervical lymphadenopathy in young adults. Extranodal disease can occur in up to 40% of patients but primary involvement of bone is rare. We present two cases of primary RDD of bone: one case of multifocal osseous RDD presenting as a painful lesion in the elbow, and one case of a solitary osseous lesion presenting as a painful lesion in the wrist.

1. Introduction

Originally described in 1969 [1], RDD traditionally has been classified as one of the non-Langerhans cell histiocytoses, a group of rare disorders characterized by the overproduction and accumulation of cells from macrophage-dendritic lineage. A more recent revision of the histiocytosis classification has proposed that the characteristics of RDD are sufficiently unique for it to merit its own category within the histiocytic disorders [2]. The most common clinical presentation of the disorder is of massive, painless cervical lymphadenopathy in children and young adults [3]. Accompanying constitutional symptoms may be present with the clinical picture mimicking lymphoma. Extranodal involvement is common, occurring in up to 40% of patients, and is particularly prevalent in older patients with the disease [4]. The most common sites of extranodal involvement include the skin, orbits, central nervous system, upper respiratory tract, and occasionally the gastrointestinal tract [5]. Bone involvement as a secondary site of RDD is thought to occur in less than 10% of patients [4]. Osseous involvement without lymphadenopathy (primary disease of bone) is rarer still and has been reported in only a small number of patients [6–9]. Primary osseous disease presents as a solitary lesion in the majority of patients [10].

We present two cases of primary osseous RDD. Case 1 is a rare case of a 76-year-old woman with multifocal primary RDD of bone presenting with a painful elbow lesion. Case 2 is a 20-year-old man presenting with a solitary painful osseous lesion in the wrist.

2. Case Presentations

2.1. Case 1. The patient is a 76-year-old woman with a two-year history of left elbow pain empirically diagnosed as gout. When her symptoms failed to improve with appropriate management, radiographs were obtained, demonstrating a lesion in the proximal radius (Figure 1) characterized as a mildly expansile lucent lesion with a thin zone of transition but no sclerotic rim. Internal osseous septations were present and there was cortical thinning but no visible cortical breakthrough, periosteal reaction, calcified matrix, or soft tissue mass. The initial differential diagnosis included metastasis, multiple myeloma, and other less common entities such as a primary sarcoma of bone or atypical infectious process. She was referred to our tertiary care hospital to consult with an oncologic orthopedic surgeon. Further history obtained at that clinic visit elicited that 3 years previously she had
incidentally discovered lytic lesions in her skull and left clavicle that were evaluated in another medical system. Biopsy of both lesions performed at that time was inconclusive showing a mix of inflammatory and fibrous cells per report. The pathologic specimens were not available for further review. Physical exam at her clinical visit was unremarkable with no palpable lymphadenopathy and no visible abnormality at the symptomatic left elbow. SPEP and UPEP tests were negative.

Her initial imaging work-up included CT of the chest, abdomen, and pelvis; contrast-enhanced MRI of the left forearm; and nuclear medicine bone scan. Her CT scan showed no findings of primary malignancy and—pertinent to her eventual diagnosis—showed no lymphadenopathy or vital organ abnormality. Bone scan demonstrated marked radiotracer uptake at the site of the lytic lesion in the proximal left radius as well as at the previously biopsied skull and left clavicle lesions (Figure 2). The MR scan of the left forearm showed a marrow replacing lesion within the proximal diaphysis of the radius (Figure 3). The lesion was T1 isointense, T2 hyperintense and demonstrated avid enhancement. Cortical thinning and small areas of cortical breakthrough not visible on the radiographs were apparent on the MRI. No associated soft tissue mass or perilesional edema was present.
Figure 3: Sagittal T1, T2 fat-suppressed, and sagittal and axial T1 fat-suppressed postcontrast images of the left forearm demonstrate a T1 isointense, T2 hyperintense, avidly enhancing lesion (arrows). The axial postcontrast image demonstrates the extent of the cortical thinning with focal areas of cortical breakthrough. There is no surrounding edema or abnormal soft tissue enhancement.

Figure 4: Histology from open biopsy of the proximal radius lesion demonstrates sheets of pale histiocytic cells in an inflammatory background (a). The histiocytes demonstrate emperiplois (engulfment of intact lymphocytes within the cytoplasm—arrowheads). The histiocytes express S100 protein by immunohistochemistry, characteristic of Rosai-Dorfman disease (b).

At the request of the orthopedic oncologist, a fluoroscopy-guided percutaneous biopsy was performed by Musculoskeletal Interventional Radiology. This rendered only tiny fragments of tissue that were nondiagnostic at histologic review. The patient then underwent open biopsy and curettage of the lesion with Orthopedic Surgery for both diagnostic and treatment purposes. Lesion histology demonstrated features diagnostic of RDD including emperiplois (engulfment of intact lymphocytes contained with the cytoplasm of histocyte cells) and positive S100 immunohistochemical staining (Figure 4). At her follow-up clinic visit 8 weeks after surgery, the patient reported resolution of her left elbow pain, and repeat radiographs demonstrated partial filling in of the lesion with healing bone (Figure 5). She was discharged from clinic and instructed to follow up if she developed recurrent left elbow symptoms or similar symptoms at a new site. One year later, she has not sought further care at our institution.
2.2. Case 2. The patient is an otherwise healthy 20-year-old incarcerated man who presented with a 1-year history of intermittent left wrist pain. Left wrist radiographs obtained as part of his initial evaluation (Figure 6) demonstrated a mildly expansile mixed lucent and sclerotic lesion in the distal left radius with multiple internal septations. The zone of transition was less well defined than in case 1 and a greater degree of cortical thinning was evident. He was referred to our facility for further evaluation. Similar to patient 1, physical exam at his clinical visit was unremarkable with no abnormality of the left wrist and no palpable lymphadenopathy. The clinical history did not reveal any additional symptoms beyond his intermittent left wrist pain. Review of a noncontrast MRI of the left wrist from an outside institution (Figure 7) demonstrated a multilobular, septated marrow replacing lesion in the distal radial metaphysis and epiphysis with more heterogeneous signal characteristics than seen in case 1. Again, no soft tissue mass or perilesional edema was present.

The patient was taken directly to open biopsy, curettage, and bone grafting with Orthopedic Surgery. Intraoperative frozen sections demonstrated an inflammatory proliferation with final diagnosis deferred to permanent. Final histologic analysis showed the same characteristic features of osseous RDD described in case 1. One month of follow-up after surgery, the patient has had relief from his wrist pain and will be followed up expectantly.

3. Discussion

RDD is a rare, nonmalignant histiocytic disorder with an as yet unknown etiology. Infectious causes—including human
herpes virus, parvovirus B19, and Epstein-Barr virus—have been proposed but with conflicting experimental results [11–14]. An association with IgG4 disease has also been suggested but proven inconsistent [2]. Recurrent KRAS and MAP2K1 mutations have been found in approximately one-third of sporadic RDD cases suggesting that at least a subset of these lesions represent clonal proliferations [15]. Based on the various clinicopathologic associations, RDD is now classified into sporadic classical (nodal), extranodal, familial, neoplasia-associated, and immune disorder-associated forms. The classical clinical presentation is massive painless cervical lymphadenopathy in a young adult frequently with associated constitutional symptoms, but extranodal involvement, often as a subcutaneous mass, is common at 40% [3, 4]. Bone involvement has been estimated at 10%, usually as a secondary process in patients with other sites of disease [4]. Primary involvement of bone is rare, estimated at 2-8% of cases [16]. Primary osseous RDD typically is solitary and has been reported in the femur, tibia, skull, clavicle, sacrum, and small bones of the hands and feet [8, 10, 16].

Patient 1 presented with a polyostotic process with a history of lesions in the skull and clavicle. Although the previous histology of the skull and clavicle lesions was inconclusive, the reported proliferation of inflammatory and fibrous cells is consistent with RDD and may represent sampling error, a known diagnostic pitfall of this entity. Further evaluation with immunohistochemical staining may have been helpful as the expression of S-100 is characteristic of RDD [17]. Emperipolesis is also characteristic but variably present [18]. In this patient, the previously biopsied lesions had similar imaging characteristics to the diagnostic lesion in her radius and her work-up for multiple myeloma or a primary malignancy was negative. This suggests that the lesions in the calvarium and clavicle may also have represented RDD. At the age of 76, she is much older than patients in previous cases series of RDD of bone that have reported a mean age of 31 for patients with osseous involvement [6]. Patient 2, at 20 years of age and with a solitary lesion, had a pattern of disease more in keeping with the previous literature on primary RDD of bone [10].

The imaging manifestations of RDD in bone are not specific to the disease. On radiographs, osseous lesions typically present with a lytic appearance with variably defined margins ranging from sclerotic to permeative [10]. Periostitis, as seen in case 2, is rare. Cortical thinning and focal breakthrough, as seen in both cases, are common. Purely sclerotic lesions have been reported but are thought to be exceedingly unusual [19]. The appearance—both on radiographs and MRI—may overlap with multiple myeloma or metastasis in the older patient and Langerhans cell histiocytosis or osteomyelitis in the younger patient, among other differential diagnostic possibilities. The majority of reported lesions have been painful but this may reflect a bias towards the detection of symptomatic sites of disease [6]. A dense inflammatory infiltrate may be more prevalent within the lesion than the characteristic histiocytes leading to sampling error and complicating histologic diagnosis from percutaneous biopsy specimens [5]. Indeed, our first patient had three nondiagnostic percutaneous biopsies prior to being diagnosed correctly after open biopsy. If RDD is contemplated in the differential, care must be taken to obtain adequate tissue for diagnosis during any percutaneous biopsy attempt.

There is no consensus treatment algorithm for primary RDD of bone. In general, RDD frequently requires no treatment and may spontaneously regress in as many as 80% of cases [20]. However, mortality has been reported in cases of vital organ involvement and secondary involvement of bone has been reported as a marker of increased risk of death [4]. In such cases with systemic involvement, treatment options include surgical resection when possible, corticosteroids,

**Figure 7:** Axial and coronal T1 and T2 fat-suppressed images through the left wrist demonstrate the lesion to be isointense on T1 and heterogeneously hyperintense on T2 with numerous internal septations.
rituximab, and a variety of chemotherapeutic agents [5, 21]. Primary RDD of bone is not thought to pose a mortality risk and treatment is focused on palliating sites of painful disease or preventing complications such as pathologic fracture. Surgical resection or curettage and bone grafting are the most commonly described interventions in these instances [10]. There is no agreed upon process for disease surveillance and many patients are managed expectantly with further imaging obtained if symptoms recur or new symptoms develop.

Primary RDD of bone is an unusual manifestation of a rare disease. The imaging appearance is nonspecific and sampling error may complicate diagnosis on the basis of percutaneous biopsy leading to delays in diagnosis and patient care. Knowledge of this uncommon entity may assist the radiologist in making a timely diagnosis.

Consent

Both patients were lost to follow-up and unable to provide consent. For this reason, the case presentation materials have been fully anonymized.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] J. Rosai and R. F. Dorfman, "Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity," Archives of Pathology & Laboratory Medicine, vol. 87, no. 1, pp. 63–70, 1969.
[2] J.-F. Emile, O. Abla, S. Fraitag et al., "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages," Blood, vol. 127, no. 22, pp. 2672–2681, 2016.
[3] W. H. McAlister, T. Herman, and L. P. Dehner, "Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)," Pediatric Radiology, vol. 20, no. 6, pp. 425–432, 1990.
[4] E. Foucar, J. Rosai, and R. Dorfman, "Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity," Seminars in Diagnostic Pathology, vol. 7, no. 1, pp. 19–73, 1990.
[5] S. Dalia, E. Sagatys, L. Sokol, and T. Kubal, "Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment," Cancer Control, vol. 21, no. 4, pp. 322–327, 2014.
[6] B. A. Mosheimer, B. Oppl, S. Zandieh et al., "Bone Involvement in Rosai-Dorfman Disease (RDD): a Case Report and Systematic Literature Review," Current Rheumatology Reports, vol. 19, no. 5, article 29, 2017.
[7] M. Sundaram, D. DeMello, S. Falbo, and R. J. Fallon, "Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) presenting with skeletal lesions," Skeletal Radiology, vol. 27, no. 2, pp. 115–117, 1998.
[8] J. C. Baker, M. Kyriakos, D. J. McDonald, and D. A. Rubin, "Primary Rosai–Dorfman disease of the femur," Skeletal Radiology, vol. 46, no. 1, pp. 129–135, 2017.
[9] A. Parekh, F. Osmani, N. Aardsma, J. Groth, and M. Gonzalez, "Osseous Rosai–Dorfman Disease Presenting as a Solitary Lesion of the Distal Radius," The Journal of Hand Surgery, 2018.
[10] E. G. Demicco, A. E. Rosenberg, I. Björnsson, L. D. Rybak, K. K. Unni, and G. P. Nielsen, "Primary rosai-dorfman disease of bone: A clinicopathologic study of 15 cases," The American Journal of Surgical Pathology, vol. 34, no. 9, pp. 1324–1333, 2010.
[11] N. Ortonne, A. M. Fillet, H. Kosuge et al., "Cutaneous Destombes-Rosai-Dorfman disease: Absence of detection of HHV-6 and HHV-8 in skin," Journal of Cutaneous Pathology, vol. 29, no. 2, pp. 113–118, 2002.
[12] M. Luppi, P. Barozzi, R. Garber et al., "Expression of human herpesvirus-6 antigens in benign and malignant lymphoproliferative diseases," The American Journal of Pathology, vol. 153, no. 3, pp. 815–823, 1998.
[13] Y. Mehraein, M. Wagner, K. Remberger et al., "Parvovirus B19 detected in Rosai-Dorfman disease in nodal and extranodal manifestations," Journal of Clinical Pathology, vol. 59, no. 12, pp. 1320–1326, 2006.
[14] W. Y. W. TSANG, T. T. C. YIP, and J. K. C. CHAN, "The Rosai–Dorfman disease histiocytes are not infected by Epstein–Barr virus," Histopathology, vol. 25, no. 1, pp. 88–90, 1994.
[15] S. Garces, L. J. Medeiros, K. P. Patel et al., "Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease," Modern Pathology, vol. 30, no. 10, pp. 1367–1377, 2017.
[16] H. M. Duijsens, F. M. Vanhoenacker, B. P. Braak ter, P. C. Hogen-doorn, and H. M. Kroon, "Primary intraosseous manifestation of Rosai-Dorfman disease: 2 cases and review of literature," Journal Belge de Radiologie - Belgisch Tijdschrift voor Radiologi, vol. 97, no. 2, pp. 84–89, 2014.
[17] M. Paulli, R. Rosso, S. Kindl et al., "Immunophenotypic characterization of the cell infiltrate in five cases of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)," Human Pathology, vol. 23, no. 6, pp. 647–654, 1992.
[18] C. Lu, T. Kuo, W. Wong, and H. Hong, "Clinical and histopathologic spectrum of cutaneous Rosai-Dorfman disease in Taiwan," Journal of the American Academy of Dermatology, vol. 51, no. 6, pp. 931–939, 2004.
[19] F. R. Patterson, M. T. Rooney, T. A. Damron, A. L. Vermont, and R. E. Hutchison, "Sclerotic lesion of the tibia without involvement of lymph nodes. Report of an unusual case of Rosai-Dorfman disease," The Journal of Bone & Joint Surgery, vol. 79, no. 6, pp. 911–916, 1997.
[20] A. Pulsoni, G. Anghel, P. Falcucci et al., "Treatment of sinus histiocytosis with massive lymphadenopathy (rosai-dorfman disease): report of a case and literature review," American Journal of Hematology, vol. 69, no. 1, pp. 67–71, 2002.
[21] O. Abla, E. Jacobsen, J. Picarsic et al., "Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease," Blood, vol. 131, no. 26, pp. 2877–2890, 2018.